AstraZeneca (NASDAQ: AZN) reported Q3 EPS of $2.08, $1.06 better than the analyst estimate of $1.02. Revenue for the quarter came in at $13.57 billion versus the consensus estimate of $13.06 billion.

Guidance:

• Given the strength of underlying Product Sales and Alliance Revenue, as well as increased confidence in achieving certain sales-based milestones, the Company raises its Total Revenue and Core EPS guidance for FY 2024 at CER.
• Total Revenue is expected to increase by a high teens percentage (previously a mid teens percentage)
• Core EPS is expected to increase by a high teens percentage (previously a mid teens percentage)

For earnings history and earnings-related data on AstraZeneca (AZN) click here.